B-Cell-Based Immunotherapy: A Promising New Alternative. Review uri icon

Overview

abstract

  • The field of immunotherapy has undergone radical conceptual changes over the last decade. There are various examples of immunotherapy, including the use of monoclonal antibodies, cancer vaccines, tumor-infecting viruses, cytokines, adjuvants, and autologous T cells carrying chimeric antigen receptors (CARs) that can bind cancer-specific antigens known as adoptive immunotherapy. While a lot has been achieved in the field of T-cell immunotherapy, only a fraction of patients (20%) see lasting benefits from this mode of treatment, which is why there is a critical need to turn our attention to other immune cells. B cells have been shown to play both anti- and pro-tumorigenic roles in tumor tissue. In this review, we shed light on the dual nature of B cells in the tumor microenvironment. Furthermore, we discussed the different factors affecting the biology and function of B cells in tumors. In the third section, we described B-cell-based immunotherapies and their clinical applications and challenges. These current studies provide a springboard for carrying out future mechanistic studies to help us unleash the full potential of B cells in immunotherapy.

publication date

  • May 31, 2022

Identity

PubMed Central ID

  • PMC9227543

Scopus Document Identifier

  • 84944463943

Digital Object Identifier (DOI)

  • 10.18632/oncotarget.4569

PubMed ID

  • 35746487

Additional Document Info

volume

  • 10

issue

  • 6